electroCore, Inc.
F:43E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
electroCore, Inc.
F:43E
|
US |
|
C
|
China Oilfield Services Ltd
F:CO9
|
CN |
|
A
|
AeroVironment Inc
XBER:JPX
|
US |
|
Tesco PLC
F:TCO2
|
UK |
|
Chocoladefabriken Lindt & Spruengli AG
LSE:0QP1
|
CH |
|
Assa Abloy AB
OTC:ASAZF
|
SE |
|
Japan Real Estate Investment Corp
OTC:JREIF
|
JP |
|
T
|
Toyota Tsusho Corp
TSE:8015
|
JP |
|
B
|
Banco de Sabadell SA
XBER:BDSB
|
ES |
|
Liberty Media Corp
NASDAQ:LSXMK
|
US |
|
Hyundai Motor Co
F:HYU
|
KR |
|
A
|
Analog Devices Inc
SWB:ANL
|
US |
|
B
|
Beiersdorf AG
XBER:BEI
|
DE |
|
Logan Energy Corp
F:R76
|
CA |
|
Roche Holding AG
OTC:RHHVF
|
CH |
|
G
|
General Dynamics Corp
SWB:GDX
|
US |
|
S
|
Silvercorp Metals Inc
LSE:0QZ2
|
CA |
|
C
|
Clicks Group Ltd
JSE:CLS
|
ZA |
|
H
|
Helix Energy Solutions Group Inc
SWB:CTV
|
US |
|
S
|
Shopify Inc
TSX:SHOP
|
CA |
|
S
|
SBFC Finance Ltd
BSE:543959
|
IN |
|
P
|
Public Storage
F:PUP
|
US |
|
Renault SA
PAR:RNO
|
FR |
|
C
|
China Life Insurance Co Ltd
OTC:CILJF
|
CN |
electroCore, Inc.
electroCore is a medical device company that sells non-invasive nerve stimulation products. Its main device line uses mild electrical pulses on the neck to stimulate the vagus nerve, which is a signal pathway connected to pain, migraine, and other body functions. The company’s products are used by patients under a doctor’s guidance, and they are designed to offer a drug-free treatment option for certain conditions. The company makes money by selling or leasing its devices and by selling disposable treatment supplies and related accessories. Its main customers include patients, physicians, clinics, and health systems that look for non-drug therapies for migraine and some other neurological or pain-related uses. electroCore also works with payers and care providers, since coverage and reimbursement can affect how easily patients adopt these treatments. What makes electroCore’s business different is that it sits at the intersection of medical devices and therapy delivery. Instead of selling a pill or a one-time procedure, it sells a repeat-use treatment system that depends on both clinical adoption and patient use at home. That gives the company a mix of device sales and recurring product revenue, while tying its fortunes to the broader move toward non-opioid and non-invasive care.
electroCore is a medical device company that sells non-invasive nerve stimulation products. Its main device line uses mild electrical pulses on the neck to stimulate the vagus nerve, which is a signal pathway connected to pain, migraine, and other body functions. The company’s products are used by patients under a doctor’s guidance, and they are designed to offer a drug-free treatment option for certain conditions.
The company makes money by selling or leasing its devices and by selling disposable treatment supplies and related accessories. Its main customers include patients, physicians, clinics, and health systems that look for non-drug therapies for migraine and some other neurological or pain-related uses. electroCore also works with payers and care providers, since coverage and reimbursement can affect how easily patients adopt these treatments.
What makes electroCore’s business different is that it sits at the intersection of medical devices and therapy delivery. Instead of selling a pill or a one-time procedure, it sells a repeat-use treatment system that depends on both clinical adoption and patient use at home. That gives the company a mix of device sales and recurring product revenue, while tying its fortunes to the broader move toward non-opioid and non-invasive care.
Record quarter: ElectroCore reported its highest revenue quarter ever at $9.6 million, up 43% year over year, with gross margin reaching 87% and adjusted EBITDA loss improving 24% to $2.3 million.
Guidance reaffirmed: Management reaffirmed full-year 2026 revenue growth guidance of approximately 30%, saying the company still expects the main growth drivers to come from the VA, Truvaga, Quell, and possible upside in TAC-STIM.
VA remains key: The VA hospital system is still the largest customer, with prescription device revenue up 48% to $7.9 million, but management said penetration is still early at roughly 2.5% of the addressable VA headache market.
Leadership impact: New COO Mike Fox said his near-term focus is deepening utilization inside the VA, expanding into Department of Defense and other federal channels, and keeping growth efficient.
Consumer efficiency: Truvaga revenue reached $1.6 million, up 44%, and management said marketing became more efficient, with ROAS improving to approximately 2.37 after shifting more spend toward affiliates and influencers.
Path to profit: Management emphasized operating leverage and said the company is not yet ready to give a specific breakeven quarter, but believes the trajectory toward profitability is clear.
Pipeline catalyst: The company highlighted PTSD-related clinical work, next-generation mobile products, and future Quell OTC and international expansion as longer-term growth drivers.
